Eton Pharmaceuticals annual free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Eton Pharmaceuticals Free Cash Flow (FCF) History (ETON)
Eton Pharmaceuticals reported $10.2M in free cash flow for fiscal 2025, an increase of 980.70% from the previous fiscal year, with a free cash flow margin of 12.75%.
View full Eton Pharmaceuticals company overviewEton Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.2M | $9.2M | +980.70% | +12.75% |
| 2024 | 2024-12-31 | $943,000 | −$5.9M | −86.16% | +2.42% |
| 2023 | 2023-12-31 | $6.8M | $2.0M | +42.48% | +21.54% |
| 2022 | 2022-12-31 | $4.8M | $9.5M | — | +22.51% |
| 2021 | 2021-12-31 | −$4.7M | $17.7M | — | −21.67% |
| 2020 | 2020-12-31 | −$22.4M | −$3.3M | — | −57425.64% |
| 2019 | 2019-12-31 | −$19.1M | −$10.7M | — | −1993.95% |
| 2018 | 2018-12-31 | −$8.4M | — | — | — |
Eton Pharmaceuticals quarterly free cash flow
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.3M | −$709,000 | −8.91% | +19.29% |
| Q1 2026 | 2026-03-31 | $7.3M | $5.2M | +250.72% | +30.21% |
| Q4 2025 | 2025-12-31 | −$11.6M | −$10.8M | — | −54.51% |
| Q3 2025 | 2025-09-30 | $11.7M | $8.8M | +297.76% | +52.28% |
| Q2 2025 | 2025-06-30 | $8.0M | $6.7M | +534.18% | +42.05% |
| Q1 2025 | 2025-03-31 | $2.1M | $4.6M | — | +12.09% |
| Q4 2024 | 2024-12-31 | −$777,000 | −$1.2M | — | −6.67% |
| Q3 2024 | 2024-09-30 | $3.0M | $2.1M | +238.14% | +28.59% |
| Q2 2024 | 2024-06-30 | $1.3M | −$5.8M | −82.33% | +13.83% |
| Q1 2024 | 2024-03-31 | −$2.5M | −$939,000 | — | −31.22% |
| Q4 2023 | 2023-12-31 | $387,000 | −$2.4M | −86.32% | +5.29% |
| Q3 2023 | 2023-09-30 | $873,000 | $2.6M | — | +12.42% |
| Q2 2023 | 2023-06-30 | $7.1M | $4.7M | +189.92% | +59.21% |
| Q1 2023 | 2023-03-31 | −$1.5M | −$2.8M | — | −29.19% |
| Q4 2022 | 2022-12-31 | $2.8M | — | — | +33.28% |
| Q3 2022 | 2022-09-30 | −$1.7M | $1.2M | — | −52.90% |
| Q2 2022 | 2022-06-30 | $2.5M | — | — | +33.30% |
| Q1 2022 | 2022-03-31 | $1.2M | — | — | +55.51% |
| Q3 2021 | 2021-09-30 | −$3.0M | $2.1M | — | −380.90% |
| Q4 2020 | 2020-12-31 | −$7.2M | −$3.3M | — | −8920.99% |
| Q3 2020 | 2020-09-30 | −$5.1M | −$1.8M | — | — |
| Q2 2020 | 2020-06-30 | −$2.9M | $2.0M | — | −14265.00% |
| Q1 2020 | 2020-03-31 | −$7.2M | −$66,000 | — | −7293.94% |
| Q4 2019 | 2019-12-31 | −$3.9M | −$2.1M | — | −845.75% |
| Q3 2019 | 2019-09-30 | −$3.2M | −$904,000 | — | — |
| Q2 2019 | 2019-06-30 | −$4.8M | −$2.6M | — | — |
| Q1 2019 | 2019-03-31 | −$7.2M | −$5.2M | — | −1431.00% |
| Q4 2018 | 2018-12-31 | −$1.8M | — | — | — |
| Q3 2018 · Sep 30 | 2018-09-30 | −$2.3M | — | — | — |
| Q2 2018 | 2018-06-30 | −$2.3M | — | — | — |
| Q1 2018 | 2018-03-31 | −$1.9M | — | — | — |
Eton Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$22.4M to $10.2M, a net increase of $32.6M. Eton Pharmaceuticals's latest reported quarter, Q2 2026, generated $7.3M in free cash flow, a decrease of 8.91% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Eton Pharmaceuticals source filings ↗Community posts
Eton begins U.S. commercialization of IMPAVIDO under exclusive rights
Eton Pharmaceuticals ($ETON) launched IMPAVIDO capsules through its U.S. rare-disease commercial organization after obtaining exclusive domestic commercialization rights. The medicine contains miltefosine and treats specified forms of leish ...
